PL2070530T3 - Leczenie chorób związanych ze stosowaniem antybiotyków - Google Patents

Leczenie chorób związanych ze stosowaniem antybiotyków

Info

Publication number
PL2070530T3
PL2070530T3 PL09156339T PL09156339T PL2070530T3 PL 2070530 T3 PL2070530 T3 PL 2070530T3 PL 09156339 T PL09156339 T PL 09156339T PL 09156339 T PL09156339 T PL 09156339T PL 2070530 T3 PL2070530 T3 PL 2070530T3
Authority
PL
Poland
Prior art keywords
antibiotics
treatment
compound
diseases associated
resistant
Prior art date
Application number
PL09156339T
Other languages
English (en)
Inventor
Youe-Kong Shue
Farah Kondori Babakhani
Franklin W Okumu
Pamela Suzanne Sears
Starr Louise Miller-Shangle
Robert Brian Walsh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PL2070530T3 publication Critical patent/PL2070530T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
PL09156339T 2004-05-14 2005-05-13 Leczenie chorób związanych ze stosowaniem antybiotyków PL2070530T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57069704P 2004-05-14 2004-05-14
EP09156339.5A EP2070530B1 (en) 2004-05-14 2005-05-13 Treatment of diseases associated with the use of antibiotics
EP05748007A EP1765312B1 (en) 2004-05-14 2005-05-13 Treatment of diseases associated with the use of antibiotics

Publications (1)

Publication Number Publication Date
PL2070530T3 true PL2070530T3 (pl) 2016-06-30

Family

ID=35428857

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10075450T PL2305245T3 (pl) 2004-05-14 2005-05-13 Leczenie chorób związanych ze stosowaniem antybiotyków (poantybiotykowych)
PL10075449T PL2305244T3 (pl) 2004-05-14 2005-05-13 Leczenie chorób związanych ze stosowaniem antybiotyków
PL09156339T PL2070530T3 (pl) 2004-05-14 2005-05-13 Leczenie chorób związanych ze stosowaniem antybiotyków

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL10075450T PL2305245T3 (pl) 2004-05-14 2005-05-13 Leczenie chorób związanych ze stosowaniem antybiotyków (poantybiotykowych)
PL10075449T PL2305244T3 (pl) 2004-05-14 2005-05-13 Leczenie chorób związanych ze stosowaniem antybiotyków

Country Status (17)

Country Link
US (2) US20070173462A1 (pl)
EP (4) EP2305244B1 (pl)
JP (2) JP5734545B2 (pl)
AT (1) ATE516024T1 (pl)
BR (1) BRPI0511119A (pl)
CA (2) CA2776682A1 (pl)
CY (2) CY1117501T1 (pl)
DK (3) DK2305245T3 (pl)
ES (4) ES2565609T3 (pl)
HU (3) HUE031581T2 (pl)
LT (1) LT2305245T (pl)
MX (2) MX344601B (pl)
PL (3) PL2305245T3 (pl)
PT (2) PT2305244T (pl)
SI (2) SI2305245T1 (pl)
TR (1) TR201902533T4 (pl)
WO (1) WO2005112990A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
BRPI0519890A2 (pt) * 2005-01-31 2009-03-31 Optimer Pharmaceuticals Inc macrociclos de 18 elementos e seus análogos
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
KR101399621B1 (ko) * 2005-10-21 2014-06-18 옵티머 파마슈티칼즈, 인코포레이티드 클로스트리듐 디피실리 관련 설사의 치료 방법
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
US20110008303A1 (en) * 2008-03-17 2011-01-13 Cedars-Sinai Medical Center Methods for treatment and prevention of mrsa/mssa
WO2011044208A1 (en) * 2009-10-06 2011-04-14 Scott Dorfner Antibiotic formulations providing reduced gastrointentestinal side effects
JP2013510900A (ja) * 2009-11-17 2013-03-28 ピラマル・ライフ・サイエンシーズ・リミテッド 炎症性疾患治療のための大環状ラクトン誘導体の使用
EP2519108A4 (en) * 2009-12-31 2013-10-16 Ira Milton Trachtman COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF INFLAMMATORY INTESTINAL DISEASE
PE20130310A1 (es) * 2010-05-18 2013-04-06 Optimer Pharmaceuticals Inc Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
EP3139932B1 (en) 2014-05-09 2018-08-01 Astellas Pharma Europe Ltd. Treatment regimen for tiacumicin compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279995A (en) 1963-05-31 1966-10-18 Allen F Reid Shaped pellets
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4918174A (en) * 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
IN186245B (pl) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
SI1527100T1 (sl) * 2002-03-29 2009-12-31 Schering Corp Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
KR100972542B1 (ko) 2002-07-29 2010-07-28 옵티머 파마슈티칼즈, 인코포레이티드 티아쿠미신 제조법
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
ZA200905337B (en) * 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
SI2305245T1 (sl) 2019-04-30
JP6101010B2 (ja) 2017-03-22
PT2305245T (pt) 2019-03-19
CA2566687A1 (en) 2005-12-01
HUE027757T2 (en) 2016-11-28
JP5734545B2 (ja) 2015-06-17
MXPA06013245A (es) 2007-05-09
ES2565609T3 (es) 2016-04-05
EP2305245A1 (en) 2011-04-06
DK2305245T3 (en) 2019-03-25
ES2608046T3 (es) 2017-04-05
TR201902533T4 (tr) 2019-03-21
DK2070530T3 (da) 2016-05-17
ES2395404T3 (es) 2013-02-12
PL2305245T3 (pl) 2019-05-31
CY1117501T1 (el) 2017-04-26
EP2070530A1 (en) 2009-06-17
US20070173462A1 (en) 2007-07-26
ATE516024T1 (de) 2011-07-15
WO2005112990A2 (en) 2005-12-01
EP1765312A2 (en) 2007-03-28
CA2776682A1 (en) 2005-12-01
EP2305245B1 (en) 2019-01-02
HUE031581T2 (en) 2017-07-28
DK2305244T3 (en) 2017-01-30
PL2305244T3 (pl) 2017-04-28
MX344601B (es) 2016-12-20
HUE043945T2 (hu) 2019-09-30
EP1765312B1 (en) 2011-07-13
JP2012197309A (ja) 2012-10-18
ES2713954T3 (es) 2019-05-24
CA2566687C (en) 2012-07-24
LT2305245T (lt) 2019-03-12
CY1121284T1 (el) 2020-05-29
BRPI0511119A (pt) 2007-11-27
PT2305244T (pt) 2016-12-29
EP1765312A4 (en) 2007-08-22
WO2005112990A3 (en) 2006-01-05
SI2070530T1 (sl) 2016-05-31
EP2305244B1 (en) 2016-10-12
EP2305244A1 (en) 2011-04-06
JP2007537290A (ja) 2007-12-20
US20130274175A1 (en) 2013-10-17
EP2070530B1 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
CY1121284T1 (el) Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
GB2480772A (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
TW200734344A (en) Antibacterial agents
GT200600114A (es) Derivados de ciclopropanocarboxamida
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
HUS1900037I1 (hu) Orális mikrobaellenes gyógyszerészeti kompozíciók
NZ597046A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
MY182720A (en) Pharmaceutical compositions
MXPA05009352A (es) Metodos y composiciones para tratamiento y prevencion de staphylococcus y otras infecciones bacterianas.
WO2006120563A3 (en) Antibacterial agents
BRPI0615614A2 (pt) compostos orgánicos
ATE427315T1 (de) Neue makrolide
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
MX2011011618A (es) Agentes terapeuticos 713.
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
BR0312211A (pt) difluortioacetamidas de oxazolidinonas como agentes antibacterianos
ECSP088132A (es) INHIBIDORES DE 6-ALQUILIDENO-PENEME B-LACTAMASA BICÍCLICOS Y COMBINACIÓN ANTIBIÓTICA DE ß-LACTAMA: UN ANTIBIÓTICO DE AMPLIO ESPECTRO
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
NZ594945A (en) Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
MX2021013833A (es) Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
EP2226388A4 (en) NEW AMINOGLYCOSIDE ANTIBIOTICUM, METHOD FOR THE MANUFACTURE THEREOF AND PHARMACEUTICAL USE THEREOF
UA99093C2 (ru) Применение фенофибрата или его производного для лечения диабетической ретинопатии
TW200716143A (en) 6-11 bridged oxime erythromycin derivatives